8-KEarnings & ResultsExhibits & Filings

Guardant Health, Inc. 8-K Report, Financial Results (Feb 20, 2025)

Filed February 20, 2025For Securities:GH

Summary

Guardant Health, Inc. (GH) has filed a Form 8-K on February 20, 2025, to announce its financial results for the fiscal quarter and full year ended December 31, 2024. The full details of these results are provided in a press release furnished as Exhibit 99.1 to the filing. This report serves as the primary channel for investors to access the company's latest financial performance data and operational updates for the fourth quarter and the entirety of 2024. Investors should review the furnished press release for critical information regarding revenue, profitability, key performance indicators, and any forward-looking guidance the company may have provided. As this filing primarily incorporates information by reference to the press release, direct engagement with Exhibit 99.1 is essential for a comprehensive understanding of Guardant Health's financial condition and operational results as of the end of 2024. The company has also included the cover page interactive data file as required.

Key Highlights

  • 1Guardant Health announced financial results for the fiscal quarter and year ended December 31, 2024, via an 8-K filing on February 20, 2025.
  • 2The detailed financial results are contained within an accompanying press release (Exhibit 99.1), which is incorporated by reference.
  • 3Investors are directed to the press release for the most up-to-date information on the company's performance.
  • 4The filing includes standard disclosures regarding the non-"filed" status of furnished information under certain SEC provisions.
  • 5Exhibit 99.1 contains the full text of the press release announcing the Q4 and full-year 2024 financial results.
  • 6The company also provided the Cover Page Interactive Data File.
  • 7This 8-K serves as the official notification of the company's latest financial reporting period.

Frequently Asked Questions

Guardant Health's financial results for the fiscal quarter and year ended December 31, 2024, are detailed in the press release furnished as Exhibit 99.1 to their Form 8-K filed on February 20, 2025. You will need to refer to this press release for the specific financial data.

No, the information furnished in this Current Report on Form 8-K, including the press release, is typically not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, unless expressly incorporated by reference into a specific filing.

Investors should look for key metrics such as total revenue, revenue growth (both year-over-year and sequential), gross margin, operating expenses, net income (or loss), earnings per share (EPS), cash flow from operations, and any updated financial guidance for future periods. Specific to Guardant Health, metrics related to test volume, average selling price, and payer coverage are also crucial.

This 8-K filing itself does not contain forward-looking statements or guidance. These are typically included in the accompanying press release (Exhibit 99.1). Investors should carefully review the press release for any forward-looking information provided by Guardant Health.